Statins for influenza: A controlled clinical study moment;Estatinas en influenza. Momento de un estudio clínico controlado

Cirugia y Cirujanos

Volumn 77, Issue 5, 2009, Pages 351-352

  Carrillo Esper, Raúl ^a  

^a Unidad de Terapia Intensiva   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL; ARTICLE; CLINICAL TRIAL; CONSULTATION; DRUG EFFECT; GENERAL SURGERY; HEALTH SERVICE; HUMAN; IMMUNE SYSTEM; INFLUENZA; MEDICAL SOCIETY; MEXICO;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS AS TOPIC; CONSULTANTS; GENERAL SURGERY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNE SYSTEM; INFLUENZA, HUMAN; MEXICO; SOCIETIES, MEDICAL;

EID: 76649134089     PISSN: 00097411     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. LipatovAS, Govorkova EA, Webby RJ. Influenza: emergence and control. J Virol 2004;78:8951-8959.
2. Johnson NP, Mueller J. Updating the accounts : global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med 2002;76:105-115.
3. 3. Kaiser L, Fritz RS, Straus SE, Gubareva L, Hayden FG Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses. J Med Virol 2001 ;64:262-268. (Pubitemid 32565121)
4. 4. Lipatov AS, Andreansky S, Webby RJ. Pathogenesis of'Hong-Kong H5N1 influenza vims NS gene reassortants in mice: the role of cytokines and B andT cell responses. J Gen Virol 2005;86:1121-1130. (Pubitemid 40485670)
5. 5.Nimmerjahn L, Dudziak D, Dirmeier U. Active NF-kB signalling is a prerequisite for influenza virus infection. J Gen Virol 2004;85:2347-2356. (Pubitemid 39162607)
6. Beigel H, Farrar H, Han AM, Haiden FG. Hyer R, De Jong MD, et al. Avian influenza A (H5N1) infections in humans. N Engl J Med 2005;353:1373-1385.
7. Ho Y, Wang JL, Wang JT, Wu UI, Chang CW, Wu HS, et al. Prognostic factors for fatal Adult influenza pneumonia. J Infect. 2009. Available at: http://www.journalofinfection.com/article/abstracts7terms?terms1 =Prognostic+factors+for+fatal+adult&terms2=&terms3=&terms4=
8. Schonbeck U, Libby P. Inflammation, immunity and HMG-CoAreductase inhibitors: statins as anti-inflammatory agents? Circulation 2004; 109:18-26.
9. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005;4:977-987.
10. 10. Merx MW, Liehn EA, Graf J, De Sandt A, Schaltenbrand M, Schrader J, et al. Statin treatment after onset of sepsis in a murine model improves survival. Circulation 2005;112:117-124. (Pubitemid 40962577)
11. 11. Almong Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004;110:880-885. (Pubitemid 39096018)
12. 12. Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G. Statin therapy is associated with fewer deaths in patients with bacteremia. Intensive Care Med 2006;32:75-79. (Pubitemid 43039379)
13. 13. Pirat A, Zeyneloglu P, Aldemir D, Yücel M, Özen O, Candan S, et al. Pretreatment with simvastatin reduces lung injury related to intestinal ischemia-reperfusion in rats. Anesth Analg 2006;102:225-232. (Pubitemid 43038312)
14. 14. Fessier MB, Young SK, Jeyaseelan S, Lieber JG. Arndt PG. Nick JA, et al. A role for hydroxy-methylglutaryl coenzyme. A reductase in pulmonary inflammation and host defense. Am J Respir Crit Care Med 2005 ;171:606-615. (Pubitemid 40365416)
15. Haidari M, Ali M, Casscells SW, Madjid M. Statins block influenza infection by down-regulating Rho/rho kinase. Circulation 2007; 116:7.
16. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res 2005;6:82-86.
17. Mancini GB, Etminan M, Zhang B. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006;47:2554-2556.
18. 18. Schlienger RG. Fedson DS, Jick S S, Jick H, Meier CR. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 2007;27:325-332. (Pubitemid 46327900)
19. 19. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007;131:1006-1012. (Pubitemid 46608700)
20. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: a population based prospective cohort study. BMJ 2006; 333:999-1004.
21. Rossignol JF, La Frazia S, Chiappa L, Ciucci A, Santoro MG. Thiazolides, a new class of antiinfluenza molecules targeting viral hemagglutinins at post-translational level. J Biol Chem 2009 Jul 28. Available at: http://www.jbc.org/cgi/reprint/M109.029470vl
22. Fedson DS. Confronting an influenza pandemic with inexpensive generic agents: can it done? Lancet Infect Dis 2008;8:571-576.
23. Fedson DS. Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis 2006;43:199-205.
24. 24. Oshitani H, Kamigaki T, Suzuki A. Major issues and challenges of influenza pandemic preparedness in developing countries. Emerg Infect Dis 2008; 14:875-880. (Pubitemid 351838594)